Literature DB >> 27720572

Stopping epilepsy treatment in seizure remission: Good or bad or both?

Dieter Schmidt1, Matti Sillanpää2.   

Abstract

PURPOSE: To review the outcome of epilepsy after stopping antiepileptic drugs in remission.
RESULTS: Stopping antiepileptic drugs (AEDs) in remission is routinely done in many patients. Although the consequences of an unexpected relapse seizure in the 2 years after stopping AEDs may cause anguish and social issues, the impact on the long term seizure outlook of the epilepsy is minimal, if any. Discontinuation of drug treatment does not seem to affect the long-term prognosis but exposes patients who were seizure-free for years to a transient two-fold risk of seizures for the first 2 years after stopping AEDs. In addition, 20% of patients who were seizure-free for years, do not become seizure-free immediately after restarting AED treatment after relapse. The list of potential pitfalls is long. Patients with juvenile myoclonic epilepsy, those with prior withdrawal attempts and late remission have a higher risk of relapse.
CONCLUSION: Stopping AEDs in remission does not affect the long-term patterns of epilepsy and some patients report a better general health in a life without AEDs. High-risk patients should not be generally encouraged to stop their AEDs in remission. We need new drugs that combine anti-seizure and antiepileptogenic effects to prevent seizure relapse and flare up of epilepsy after stopping AEDs in remission.
Copyright © 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AED withdrawal: long-term seizure prognosis; Drug-treated epilepsy; Natural course; Pitfalls in stopping AEDs; Relapse seizures; Stopping AEDs

Mesh:

Substances:

Year:  2016        PMID: 27720572     DOI: 10.1016/j.seizure.2016.09.003

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

Review 1.  Discontinuation of antiepileptic drugs in adults with epilepsy.

Authors:  Hanka Laue-Gizzi
Journal:  Aust Prescr       Date:  2021-04-01

2.  Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US.

Authors:  Shehryar R Sheikh; Michael W Kattan; Michael Steinmetz; Mendel E Singer; Belinda L Udeh; Lara Jehi
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

3.  Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs.

Authors:  Margherita Contento; Bruno Bertaccini; Martina Biggi; Matteo Magliani; Ylenia Failli; Eleonora Rosati; Luca Massacesi; Marco Paganini
Journal:  Epilepsia       Date:  2021-07-12       Impact factor: 5.864

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.